ARTV ARTIVA BIOTHERAPEUTICS INC
Health Care · Russell 2000
Next earnings: Thu 12 Nov 2026 · estimated
What 8 analyst firms say about ARTIVA BIOTHERAPEUTICS INC: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
8 rated views · 9 analyst/firm records · 8 firms
Radar score
- Russell 2000 · Top Picks · 6MNot scored · Price below 5 USD
- Russell 2000 · Safest consensus · 6MNot scored · Price below 5 USD
Recent analyst activity · last 90 days
Our tracked history has 8 reports on ARTV from 7 analyst firms in the last 90 days (8 firms in the past year).
Comparing each firm's latest target with its previous one: 2 lowered it and 1 left it unchanged.
Ratings, latest available report against the previous one: 0 upgrades and 3 downgrades.
Latest observed target change: Jefferies lowered its target from $23.00 (set 12 Mar 2026) to $4.00 on 29 Oct 2026.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| Cantor Fitzgerald | Josh Schimmer | Buy | 2 Oct 2026 | 40.00 USD |
| H.C. Wainwright | Emily Bodnar | Buy | 2 Oct 2026 | 35.00 USD · 7 Aug 2026 |
| Jefferies | Roger Song | Hold | 28 Oct 2026 | Conflicting reports · excluded |
| Needham | Gil Blum | Hold | 27 Oct 2026 | 41.00 USD · 8 Jun 2026 |
| TD Cowen | Tyler Van Buren | Hold | 27 Oct 2026 | — |
| Wedbush | David Nierengarten | Hold | 27 Oct 2026 | 4.00 USD |
| Wedbush | Martin Fan | Hold | 27 Oct 2026 | 4.00 USD |
| Weiss Ratings | Unnamed analyst | — | 19 Oct 2026 | — |
| Data feed RESEARCH | Research Team | Hold | 15 Jun 2026 | — |
Partial coverage · checked 6 Nov (6 Nov 2026, 07:40 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.